In an open-label extension of the CLARITY-AD study, treatment with IV lecanemab was associated with significant improvement in Alzheimer’s disease-related pathology, continuing a positive ...

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in people with early Alzheimer's disease.

OLE Study Explores Biomarkers and Clinical Effects Across Five Years An OLE with 10 mg/kg IV biweekly lecanemab dosing was implemented after analysis of the 18-month, core phase (Study 201, Alz ...

In the open-label extension, a responder analysis suggested that lecanemab delayed progression to the next Alzheimer's stage based on CDR-SB scores by 30% (HR 0.704, 95% CI 0.59-0.84).